The bisphosphonate YM529 inhibits osteoblastic bone tumor proliferation of prostate cancer
The bisphosphonate YM529 inhibits osteoblastic bone tumor proliferation of prostate cancer
复制标题
DOI：
10.1002/pros.20592
复制
发表时间：
2007-06
期刊：
影响因子：
--
通讯作者：
H. Yonou;A. Ochiai;Satoshi Ashimine;H. Maeda;Y. Horiguchi;K. Yoshioka;Y. Ogawa;T. Hatano;M. Tachibana
中科院分区：
文献类型：
--
作者：
H. Yonou;A. Ochiai;Satoshi Ashimine;H. Maeda;Y. Horiguchi;K. Yoshioka;Y. Ogawa;T. Hatano;M. Tachibana
在男性中，前列腺癌经常转移到骨骼，在那里它形成具有引起疼痛的溶骨性元素的成骨细胞病变。然而，破骨细胞生成在人前列腺癌骨转移中的作用尚不清楚。已知双膦酸盐对治疗溶骨性骨转移有益，因此我们采用人前列腺癌成骨细胞骨肿瘤模型来研究新的双膦酸盐（YM529：米诺膦酸盐）是否可以抑制骨肿瘤的形成和已建立的成骨细胞肿瘤的进展。
In men, prostate cancer frequently metastasizes to the bones, where it forms osteoblastic lesions with an osteolytic element that cause pain. However, the role of osteoclastogenesis in bone metastasis of human prostate cancer is unknown. Bisphosphonates are already known to be beneficical for treating osteolytic bone metastases, so we employed a model of osteoblastic bone tumor of human prostate cancer to investigate whether a new bisphosphonate (YM529: minodronate) could inhibit both the formation of bone tumors and the progression of established osteoblastic tumors.